Basic Information
Axumin
Regulatory Information
EMEA/H/C/004197
May 21, 2017
March 22, 2017
18
October 8, 2024
Company Information
ιreland
6th Floor, 2 Grand Canal Square Dublin 2
Blue Earth Diagnostics Ltd
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication This medicinal product is for diagnostic use only. Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Axumin. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Axumin. For practical information about using Axumin, patients should read the package leaflet or contact their doctor or pharmacist.